AZNCF News and Press, AstraZeneca Plc From 06/02/20

Have you ever found yourself saying a stock is too expensive because it's made a big move in a short period of time? Or that a stock is too cheap to ignore because its price has fallen sharply? Anchoring bias, or the tendency to fixate on a past price when considering a new investment idea, ca...

Background AstraZeneca ( AZN ) has been a strong stock market performer the past few years despite the following unimpressive results, as presented on page 2 of its 2019 Annual Report and comparing 2017 with 2019: revenues up 8.5% net cash flow from operating activities down 17% re...

The only reason to sell them a stock now is to buy other, more attractive stocks. If you can't find more attractive stocks, hold on to what you have. - Sir. John Templeton In late 2019, Clovis Oncology ( CLVS ) was trading as low as $3.21. After I issued my buy recommendation, Clovis s...

AstraZeneca and Merck Receive Lynparza Boost AstraZeneca ( AZN ) and Merck & Co. ( MRK ) announced that their Lynparza has received the FDA nod for its fourth tumor type, prostate cancer. This PARP inhibitor is now authorized to be used for treating patients with previously treated m...

AstraZeneca PLC ( AZN ) has not only bounced after COVID-19 sell-off but is also now posting new highs. Few doubt that AZN has a number of strong new medicines and a good pipeline, but we are bearish on the stock as we believe this future growth is well priced in. We see more downside risk to ...

The Rodney Dangerfield effect continues for those leading the commonly shunned big pharma sector. AstraZeneca ( AZN ) remains the face of this indifference. In early February of this year, I wrote AstraZeneca Remains An Attractive Total Return Trade In 2020 And Beyond , the second of two a...

Quick Take Lantern Pharma ( LTRN ) intends to raise $25 million in gross proceeds from an IPO of its common stock, per an amended registration statement . The company is advancing a pipeline of drug treatment candidates identified by its proprietary RADR platform. LTRN believes it can b...

Quick Take ADC Therapeutics ( ADCT ) intends to raise $125 million from the sale of its common stock, per an amended registration statement . The company is advancing a pipeline of drug candidates for the treatment of blood cancers and solid tumors. ADCT is making a new attempt to go pu...

Background This is Part 2 of a 2-part set of articles about Gilead ( GILD ); Part 1 focused on its remdesivir ("RDV") for COVID-19. There is probably more going on at GILD than the focus on RDV in GILD's recent Q1 earnings report and conference call could allow to be discussed. The ...

Previously, I wrote how indiscriminate buying would be replaced with selectivity and that the market was approaching an important make-or-break moment following its rapid run-up since March. The S&P 500 remains below critical resistance, so the risk of weakness remains. However, our ...